These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29627155)

  • 1. Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study.
    Ilyas A; Hashim Z; Channa IS; Zarina S
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):241-250. PubMed ID: 29627155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective.
    Ilyas A; Hashim Z; Zarina S
    Mol Cell Biochem; 2015 Jul; 405(1-2):53-61. PubMed ID: 25854900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy.
    Xi S; Peng Y; Minuk GY; Shi M; Fu B; Yang J; Li Q; Gong Y; Yue L; Li L; Guo J; Peng Y; Wang Y
    J Ethnopharmacol; 2016 Aug; 190():1-12. PubMed ID: 27235019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
    Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
    Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genistein induces apoptosis by down-regulating thioredoxin-1 in human hepatocellular carcinoma SNU-449 cells.
    Roh T; Kim SW; Moon SH; Nam MJ
    Food Chem Toxicol; 2016 Nov; 97():127-134. PubMed ID: 27597132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
    Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
    World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells.
    Im E; Yeo C; Lee EO
    Life Sci; 2018 Sep; 209():259-266. PubMed ID: 30107166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
    Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
    Ren J; Li G; Zhao W; Lin L; Ye T
    World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
    Tan J; Ye J; Song M; Zhou M; Hu Y
    J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TQ inhibits hepatocellular carcinoma growth in vitro and in vivo via repression of Notch signaling.
    Ke X; Zhao Y; Lu X; Wang Z; Liu Y; Ren M; Lu G; Zhang D; Sun Z; Xu Z; Song JH; Cheng Y; Meltzer SJ; He S
    Oncotarget; 2015 Oct; 6(32):32610-21. PubMed ID: 26416455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kurarinol induces hepatocellular carcinoma cell apoptosis through suppressing cellular signal transducer and activator of transcription 3 signaling.
    Shu G; Yang J; Zhao W; Xu C; Hong Z; Mei Z; Yang X
    Toxicol Appl Pharmacol; 2014 Dec; 281(2):157-65. PubMed ID: 24997323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
    Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.